Celldex Therapeutics, Inc.
| Nasdaq: CLDX
Celldex Therapeutics, Inc. is an innovative biotechnology company focused on the discovery, development and commercialization of immunotherapies. Its lead drug candidates include CDX-110, CDX-011, and CDX-1127. The company has additional clinical and preclinical programs, including CDX-1401, CDX-301and CDX-1135. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Needham, MA.